Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions? [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling you about value. The stock has a small 0.2% return over the past week and is roughly flat over 30 days, while year to date it is up 11.2%. The 1 year return reflects a 28.5% decline and the 3 year return a 46.0% decline. Recent attention on the company has centered on its role in applying technology and data driven approaches to drug discovery. This has kept it on the radar of investors watching the biotech and AI intersection, and helps frame why the share price can move sharply as sentiment around that theme shifts. On our checks, Recursion scores 4 out of 6 for potential undervaluation, which you can see in detail in its valuation score . Next we look at how different valuation methods line up on the stock, before finishing with a framework that can help you judge whether those nu
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 1/20/26 - Form 144
- 1/12/26 - Form 8-K
- 1/9/26 - Form 3
- RXRX's page on the SEC website